If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
AbbVie Inc. (NYSE:ABBV), a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
If You Bought AbbVie Stock 10 Years Ago
The company's stock traded at approximately $64.32 per share 10 years ago. If you had invested $10,000, you could have bought roughly 155 shares. Currently, shares trade at $193.34, meaning your investment's value could have grown to $30,059 from stock price appreciation alone. However, AbbVie also paid dividends during these 10 years.
Don't Miss:
AbbVie's dividend yield is currently 3.39%. Over the last 10 years, it has paid about $45.67 in dividends per share, which means you could have made $7,100 from dividends alone.
Summing up $30,059 and $7,100, we end up with the final value of your investment, which is $37,159. This is how much you could have made if you had invested $10,000 in AbbVie stock 10 years ago. This means a total return of 271.59%. In comparison, S&P 500 total return for the same period is 221.50%.
What Could The Next 10 Years Bring?
AbbVie has a consensus rating of "Buy" and a price target of $200.03 based on the ratings of 34 analysts. The price target implies more than a 3% potential upside from the current stock price.
Trending: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation.
On April 25, the company announced its Q1 2025 earnings, posting adjusted EPS of $2.46, up 6.5% year-over-year, and beating the consensus of $2.38, as reported by Benzinga.
The pharmaceutical giant reported sales of $13.34 billion, coming in above the consensus of $12.92 billion.
'AbbVie's first-quarter results were well ahead of our expectations and reflect an excellent start to the year,' said CEO Robert Michael. 'The fundamentals of our business are strong, and we continue to bolster our outlook with pipeline advancements and strategic investments. Based on the progress we are making, AbbVie is well positioned for the long term.'
The company raised its full-year 2025 adjusted EPS from the range of $11.99 to $12.19 to $12.09 to $12.29, compared to the consensus of $12.17.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
US stock futures fall after Trump raises tariff tensions
U.S. stock futures are lower after President Donald Trump raises tariff tensions again by promising unilateral tariff rates within two weeks. He said he will send letters to trading partners in the next couple of weeks setting unilateral tariff rates, ahead of a July 9 deadline to reimpose higher duties on dozens of economies. Trump's new tariff threat contrasts with the more positive tone officials tried to strike after reaching a trade framework with China in London and earlier remarks from Treasury Secretary Scott Bessent. Bessent said at a hearing before the House Ways and Means Committee that the Trump administration though was open to extending the current 90-day tariff pause beyond July 9 for the U.S.′ top trading partners, as long as they show 'good faith' in ongoing trade negotiations. Futures linked to the blue-chip Dow fell -0.60%, while broad S&P 500 futures dropped -0.41% and tech-heavy Nasdaq futures slipped -0.35.%. Another set of inflation data are due before the opening bell. Producer prices, or the the prices businesses pay for their goods and services, are expected to rise 2.3% on an annual basis in May, according to Bank of America economists. Without the volatile food and energy sectors, producer prices are seen up 2.7%, they said. Some economists expect some tariff-related inflation to appear as inflation first can be seen by businesses, before price increases are passed on to consumers. Oracle's results in the final three months of its fiscal year topped Street views. The company also said cloud infrastructure revenue will rise by more than 70% in fiscal 2026, up from a 50% growth rate in the prior fiscal year. Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday morning. This article originally appeared on USA TODAY: US stock futures fall after Trump raises tariff tensions Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28 minutes ago
- Yahoo
Is Fidelity Select Portfolio Medical Technology and Devices (FSMEX) a Strong Mutual Fund Pick Right Now?
If you have been looking for Sector - Health funds, a place to start could be Fidelity Select Portfolio Medical Technology and Devices (FSMEX). FSMEX has a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on various forecasting factors like size, cost, and past performance. Zacks categorizes FSMEX as Sector - Health, a segment packed with options. Sector - Health mutual funds offer investors a focus on the healthcare industry, one of the largest sectors in the American economy. These funds can include everything from pharmaceutical companies to medical device manufacturers and for-profit hospitals. Fidelity is responsible for FSMEX, and the company is based out of Boston, MA. Fidelity Select Portfolio Medical Technology and Devices made its debut in April of 1998, and since then, FSMEX has accumulated about $4.48 billion in assets, per the most up-to-date date available. The fund is currently managed by Edward Yoon who has been in charge of the fund since May of 2007. Investors naturally seek funds with strong performance. This fund has delivered a 5-year annualized total return of 5.12%, and it sits in the middle third among its category peers. If you're interested in shorter time frames, do not dismiss looking at the fund's 3 -year annualized total return of 3.37%, which places it in the bottom third during this time-frame. It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower. When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. Over the past three years, FSMEX's standard deviation comes in at 18.22%, compared to the category average of 15.64%. Over the past 5 years, the standard deviation of the fund is 19.24% compared to the category average of 16.64%. This makes the fund more volatile than its peers over the past half-decade. Investors should note that the fund has a 5-year beta of 0.92, which means it is hypothetically less volatile than the market at large. Alpha is an additional metric to take into consideration, since it represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which in this case, is the S&P 500. With a negative alpha of -7.95, managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns. Costs are increasingly important for mutual fund investing, and particularly as competition heats up in this market. And all things being equal, a lower cost product will outperform its otherwise identical counterpart, so taking a closer look at these metrics is key for investors. In terms of fees, FSMEX is a no load fund. It has an expense ratio of 0.63% compared to the category average of 1.11%. Looking at the fund from a cost perspective, FSMEX is actually cheaper than its peers. While the minimum initial investment for the product is $0, investors should also note that there is no minimum for each subsequent investment. Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included. Overall, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) has a high Zacks Mutual Fund rank, and in conjunction with its comparatively similar performance, average downside risk, and lower fees, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) looks like a great potential choice for investors right now. Your research on the Sector - Health segment doesn't have to stop here. You can check out all the great mutual fund tools we have to offer by going to to see the additional features we offer as well for additional information. For analysis of the rest of your portfolio, make sure to visit for our full suite of tools which will help you investigate all of your stocks and funds in one place. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Get Your Free (FSMEX): Fund Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28 minutes ago
- Yahoo
2 Industrial Mutual Funds to Buy on Manufacturing Resurgence
With inflation easing and interest rate cuts inching slowly closer on the Fed's radar, Industrial mutual funds have emerged as one of Wall Street's standout sectors in 2025. The U.S. ISM manufacturing PMI recently hit a nine-month high, signaling a manufacturing resurgence that typically leads equity performance. Although still in contraction territory, rising orders and improving momentum suggest manufacturing firms may be on the verge of a breakout. This cyclical recovery makes industrial stocks attractive, especially at valuations that lag behind defensive sectors. Also, reshoring and supply chain independence are reshaping global production. Companies are bringing manufacturing back to domestic soil. This not only boosts demand for factory equipment and transportation assets but also benefits firms in construction, logistics and machinery. On cue, the S&P 500 Industrials Select Sector SPDR (XLI) has advanced 8.7% year to date. Industrials are riding the wave of long-term investment in infrastructure and green energy. Higher-for-longer interest rates may dampen some tech aspirations, yet industrial names tied to infrastructure upgrades and electric grid modernization remain well-positioned. Specialized industrial segments like defense, transportation and aerospace also reap the rewards of elevated government spending and corporate capital allocation. In summary, industrial mutual funds are thriving because they sit at the crossroads of pro-cyclical momentum, structural manufacturing trends and infrastructure policies. They offer a combination of value, growth and inflation protection. As long as reshoring efforts intensify and infrastructure investments persist, these funds are likely to remain a Wall Street favorite through the rest of 2025. Industrial mutual funds provide much-needed stability and growth potential. Hence, astute investors should consider such funds at present. Mutual funds, in general, reduce transaction costs and diversify portfolios without an array of commission charges that are mostly associated with stock purchases (read more: Mutual Funds: Advantages, Disadvantages, and How They Make Investors Money). We have thus selected two industrial mutual funds that boast a Zacks Mutual Fund Rank #1 (Strong Buy) or 2 (Buy), have positive three-year and five-year annualized returns and minimum initial investments within $5000, and carry a low expense ratio. Fidelity Select Defense & Aerospace FSDAX primarily invests in common stocks. It invests the majority of its assets in securities of companies principally engaged in the research, manufacture, or sale of products or services related to the defense or aerospace industries. FSDAX advisors use fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. Clayton Pfannenstiel has been the lead manager of FSDAX since December 2021. Three top holdings for FSDAX are 20.9% in General Electric, 11.9% in Boeing and 10% in Raytheon. FSDAX's 3-year and 5-year annualized returns are 17.8% and 16.3%, respectively. Its net expense ratio is 0.65%. FSDAX has a Zacks Mutual Fund Rank #1. To see how this fund performed compared to its category, and other 1 and 2 Ranked Mutual Funds, please click here. Fidelity Select Industrials Portfolio FCYIX primarily invests in common stocks. It invests the majority of its assets in securities of companies principally engaged in the research, development, manufacture, distribution, supply, or sale of industrial products, services, or equipment. FCYIX advisors use fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. David Wagner has been the lead manager of FCYIX since June 2023. Three top holdings for FCYIX are 7.1% in General Electric, 6.1% in Howmet Aerospace and 5.2% in GE Vernova. FCYIX's 3-year and 5-year annualized returns are 16.3% and 17.3%, respectively. Its net expense ratio is 0.69%. FCYIX has a Zacks Mutual Fund Rank #2. Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Get Your Free (FCYIX): Fund Analysis Report Get Your Free (FSDAX): Fund Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
